Advertisement
Roche
Subscribe to Roche

The Lead

Drugmakers Bet on Ebola Vaccines, Treatments

October 26, 2014 9:33 am | by Matthew Perrone - Associated Press - Associated Press | News | Comments

Drugmakers are racing to develop vaccines and drugs to address the worst outbreak of Ebola in history. It's unclear who will pay for their products, but companies are betting that governments and aid groups will foot the bill.    

NewLink Genetics Rises on Roche Cancer Partnership

October 20, 2014 2:59 pm | News | Comments

NewLink said it will get $150M upfront from Genentech, and could receive more than $1B in...

FDA Approves Esbriet to Treat Idiopathic Pulmonary Fibrosis

October 16, 2014 8:41 am | News | Comments

Idiopathic pulmonary fibrosis is a condition in which the lungs become progressively scarred...

Roche Posts Flat Nine-Month Sales

October 16, 2014 8:14 am | by JOHN HEILPRIN, Associated Press | News | Comments

Roche Holding AG posted flat sales for the first nine months of 2014, but said Thursday the...

View Sample

FREE Email Newsletter

FDA Grants Priority Review for Genentech’s Lucentis in Diabetic Retinopathy

October 8, 2014 3:35 pm | News | Comments

Genentech announced that the FDA has accepted to file the company's supplemental Biologics License Application and granted Priority Review of Lucentis® for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans. The FDA confirmed action date is February 6, 2015.

Roche Ranked Most Sustainable Healthcare Company in the Dow Jones Sustainability Indices

September 11, 2014 11:25 am | News | Comments

For the sixth consecutive year, Roche has been recognized by the Dow Jones Sustainability Indices (DJSI) as the Group Leader in sustainability within the pharmaceuticals, biotechnology and life sciences industry. This places Roche amongst the top 10 percent of companies across all surveyed industries.

Roche to Buy InterMune for $8.3B

August 25, 2014 8:10 am | News | Comments

Roche said Sunday it has reached an $8.3 billion deal to buy InterMune Inc., a California-based developer of treatments for lung diseases.                   

Advertisement

FDA Approves Genentech’s Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer

August 15, 2014 8:23 am | News | Comments

Genentech, a member of the Roche Group, announced that the FDA approved Avastin® (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix.

AstraZeneca and Roche to Develop Companion Diagnostic Test for AZD9291

July 28, 2014 7:57 am | News | Comments

AstraZeneca today announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291, AstraZeneca’s investigational compound in clinical development for non-small-cell lung cancer (NSCLC).

Roche Posts Seven Percent Profit Drop

July 24, 2014 2:29 am | by The Associated Press | News | Comments

Swiss drugmaker Roche Holding AG on Thursday posted a net profit drop of 7 percent compared with a year ago, weighed down by a strong Swiss franc and charges from one of its diagnostic units.          

FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer

July 22, 2014 8:13 am | News | Comments

Genentech, a member of the Roche Group, today announced that the FDA has accepted the company's supplemental Biologics License Application and granted Priority Review for Avastin® plus chemotherapy for the treatment of women with recurrent platinum-resistant ovarian cancer.

Genentech Alzheimer's Drug Misses Goals in Studies

July 16, 2014 1:45 pm | by MARILYNN MARCHIONE, AP Chief Medical Writer | News | Comments

An experimental drug from Genentech failed to slow mental decline in mid-stage studies on more than 500 people with mild to moderate Alzheimer's disease, but showed some promise in the least-impaired participants who received a higher dose.  

Advertisement

FDA Grants Roche’s Avastin Priority Review for Certain Types of Cervical Cancer

July 15, 2014 8:38 am | News | Comments

Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for the treatment of women with persistent, recurrent or metastatic cervical cancer.

Genentech’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf® Meets Phase III Endpoint

July 14, 2014 8:24 am | News | Comments

The study demonstrated that the investigational MEK inhibitor cobimetinib, used in combination with Genentech’s BRAF inhibitor Zelboraf, helped patients with previously untreated BRAF V600 mutation-positive advanced melanoma live significantly longer without their disease worsening.

Roche Buying Seragon in U.S. for Up to $1.7B

July 2, 2014 4:29 am | by The Associated Press | News | Comments

Roche Holding AG says its U.S.-based biotech company Genentech has agreed to acquire American biotechnology firm Seragon Pharmaceuticals, Inc. for up to $1.725 billion in cash and contingency payments.        

Roche Acquires Genia Technologies

June 2, 2014 8:34 am | News | Comments

Roche announced today the acquisition of Genia Technologies, Inc., a privately held company, based in Mountain View, California, USA. Genia is developing a single-molecule, semiconductor based, DNA sequencing platform using nanopore technology.

Italy Seeks $1.6B in Damages from Novartis and Roche

May 29, 2014 1:45 pm | News | Comments

Italy's health ministry is seeking 1.2 billion euros ($1.63 billion) in damages from Swiss pharmaceutical giants Novartis and Roche after an anti-trust court ruled the two companies colluded to prevent the distribution of an eye medication.  

Advertisement

FDA Approves First HPV Test for Primary Cervical Cancer Screening

April 25, 2014 8:26 am | News | Comments

The FDA has approved the first FDA-approved HPV DNA test for women 25 and older that can be used alone to help a health care professional assess the need for a woman to undergo additional diagnostic testing for cervical cancer.    

DNA Alternative to Pap Smear Sparks Medical Debate

April 15, 2014 1:41 pm | by MATTHEW PERRONE, AP Health Writer | News | Comments

A high-tech screening tool for cervical cancer is facing pushback from more than a dozen U.S. patient groups, who warn that the genetic test could displace a simpler, cheaper and more established mainstay of women's health: the Pap smear.  

FDA Committee Recommends Roche's HPV Test for Detection of Cervical Cancer

March 13, 2014 8:27 am | News | Comments

Roche has announced FDA Microbiology Devices Panel of the Medical Devices Advisory Committee recommended unanimously that the benefits of the cobas HPV (Human Papillomavirus) Test as a first-line primary screening tool in women 25 years and older to assess their risk of cervical cancer based on the presence of clinically relevant high-risk HPV DNA outweigh the risks.

Roche Names New Head of Oncology Research

March 6, 2014 1:52 pm | News | Comments

Roche announced today that William Pao, M.D., Ph.D., Professor of Medicine and Head of the Hematology-Oncology Division at Vanderbilt University Medical Center in the US, will join Roche Pharma Research and Early Development (pRED) as Global Head of the Oncology Disease and Translational Area.

Genentech Ends Phase III Lung Cancer Study

March 3, 2014 8:40 am | News | Comments

Genentech, a member of the Roche Group, announced today that an independent data monitoring committee has recommended that the Phase III METLung study be stopped due to a lack of clinically meaningful efficacy.       

Pharma Data Play Larger Role in Olympic Drug Tests

February 10, 2014 8:34 am | by MATTHEW PERRONE, AP Health Writer | News | Comments

Some of the world's biggest drugmakers are playing a larger role in anti-doping efforts at this year's Winter Olympics: They're providing information on drugs that once would have been considered proprietary trade secrets.     

PDL Biopharma Settles Roche Royalty Fight

February 4, 2014 8:24 am | News | Comments

PDL Biopharma has agreed to settle its disputes with Swiss drugmaker Roche over royalty rates on a group of drugs PDL helped develop. The dispute concerned four cancer drugs: Avastin, Herceptin, Kadcyla, and Perjeta; also involved were the asthma treatment Xolair, and Lucentis, an eye drug.

Advancing Clinical Science Through Data Sharing

February 3, 2014 8:54 am | Videos | Comments

In response to advances in technology and the increasing needs of society, Roche has implemented a broader data sharing policy. The company's new policy provides access to summary data in the form of clinical study reports (CSRs), and analyzable patient level data sets

Roche Reports Strong Profit, Expects Growth in 2014

January 30, 2014 8:14 am | by JOHN HEILPRIN, Associated Press | News | Comments

Strong demand for its cancer medicines and diagnostic tests used by clinical laboratories boosted Swiss drug maker Roche's full-year profits, the company reported Thursday.             

Prothena to Receive $30M Upfront Payment from Roche

January 23, 2014 9:33 am | News | Comments

Prothena Corporation announced today that, pursuant to its License, Development, and Commercialization Agreement with Roche, it will receive the $30 million upfront payment from Roche as a result of the License Agreement having become effective upon the expiration of the Hart-Scott-Rodino waiting period.

Roche Provides Update on the First Two of Six Phase III Schizophrenia Studies

January 21, 2014 8:48 am | News | Comments

Roche today announced that two phase III studies of its investigational medicine bitopertin (RG1678) in adults with persistent, predominant negative symptoms of schizophrenia failed to meet their primary endpoints.      

Roche and Prothena to Devlop Antibodies for Parkinson's Disease

December 11, 2013 4:13 pm | News | Comments

Roche and Prothena Corporation have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease, which is currently in preclinical development and is expected to enter Phase 1 clinical trials in patients with Parkinson's disease in 2014.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading